|1.||Zhou, Yi: 4 articles (01/2010 - 09/2008)|
|2.||Chen, Shun: 3 articles (09/2009 - 04/2008)|
|3.||Braun, Barry: 3 articles (02/2009 - 06/2006)|
|4.||Wang, Ming-Shu: 3 articles (09/2008 - 04/2008)|
|5.||Cheng, An-Chun: 3 articles (09/2008 - 04/2008)|
|6.||Ngwa, Wilfred: 2 articles (09/2015 - 02/2015)|
|7.||Sajo, Erno: 2 articles (09/2015 - 02/2015)|
|8.||Kumar, Rajiv: 2 articles (09/2015 - 02/2015)|
|9.||Violari, Avy: 2 articles (07/2015 - 02/2014)|
|10.||Cotton, Mark F: 2 articles (07/2015 - 02/2014)|
05/01/2014 - "In vivo, Def + Van combination therapy significantly reduced the bacterial burden in mice kidneys (p = 0.005) and spleen (p < 0.001), and reduced the severity of infection with MRSA or VISA strains compared to placebo-treated mice. "
09/18/2009 - "Following AHV-1 infection, DEF showed morphological changes such as cell rounding, improved refractivity and detachment from the culture surface. "
01/01/2002 - "Although parent and Henle-NO(def) cells differed markedly in their ability to produce NO after infection, they eliminated S. "
11/01/2013 - "In this study, we examined i) whether macrophage PON2 participates in 3OC(12)-HSL hydrolysis, ii) the effect of PON2 deficiency in acute PAO1 infection in mice and iii) the effect of 3OC(12)-HSL on PON2 deficient (PON2-def) macrophages. "
12/02/2015 - "Transmission electron microscopy revealed that the virus triggered DEF cell membrane invagination as early as 10min post-infection and that integrated endocytic vesicles formed at 20min post-infection. "
07/01/2008 - "Tumor volumes based on pathologic examination (gold standard), CT, SUV(def), SUV-1SD, SUV2.5, and SUV40 were analyzed. "
09/21/2015 - "Results also showed that the DEF increased with increasing field size or decreasing tumor volume, as expected. "
09/21/2015 - "The DEF for IR was then compared with that for IV. For IR with 3.5 times higher concentrations than IV, and 2 cm diameter tumor, clinically significant DEF values of up to 1.19, 1.26, and 1.51 were obtained for CNPs, CBNPs and GNPs. "
01/01/2013 - "To analyze the effects of a new unknown peptide DEF on the growth of tumor cells, a fused polypeptide TAT-DV1-DEF was designed and synthesized. "
06/01/2012 - "The largest adjustment was made in patients with substantially regressing tumors: ROI(def) = 11.8 ± 10.9 cm(3) vs. ROI(def_ad) = 5.9 ± 7.8 cm(3) vs. ROI(m) = 7.7 ± 7.2 cm(3) (p = 0.57). "
02/01/2005 - "The aim of this study was to test whether, in patients undergoing coronary artery bypass grafting (CABG), DEF i.v. infusion can reduce reperfusion injury on a short- and long-term basis. "
02/24/2004 - "Susceptibility to myocardial ischemia-reperfusion injury was determined in Langendorff-perfused hearts isolated from wild-type mice (WT) and mice lacking G6PD (G6PD(def)) (20% of WT myocardial G6PD activity). "
02/01/2005 - "In patients undergoing CABG, DEF i.v. infusion ameliorates oxygen free radical production and protects the myocardium against reperfusion injury. "
11/15/2002 - "By contrast, the Cr2(def) mice have reduced injury in the IgM-dependent model of reperfusion injury. "
08/01/2000 - "However, coadministration of DEF and tempol did not produce any additional beneficial actions against renal ischemia/reperfusion injury or against oxidative stress-mediated PT cell injury/death. "
|4.||Stomach Neoplasms (Stomach Cancer)
01/01/2006 - "DEF is effective in the treatment of advanced gastric cancer, and has a good safety profile."
01/01/1993 - "The authors have hypothesized that iodine-deficiency (I-def) or in some cases iodine-excess (I-excess) is associated with the development of gastric cancer. "
01/01/1993 - "These data enable us to hypothesize that I-def or I-excess might constitute a new risk factor for gastric cancer, both by regulating gastric trophism and by antagonizing the action of those I-inhibitors (such as nitrates, thiocyanate and salt) previously studied as risk factors for gastric cancer."
01/01/2006 - "This study evaluated the efficacy and safety of docetaxel, epirubicin, and 5-fluorouracil (5-FU) [DEF] as treatment for locally advanced unresectable or metastatic gastric cancer. "
01/01/2006 - "Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen."
|5.||Wounds and Injuries (Trauma)
03/01/2011 - "Trauma injury severity scores (TRISS) were used to calculate survival probability for TCC-P and DEF. "
12/01/2008 - "The Ws statistic was introduced over 10 years ago to quantify the performance of trauma care systems through definitive outcome based evaluation (DEF) methods. "
03/01/2011 - "We hypothesized that temporary chest closure with or without intrathoracic packing (TCC-P) as a method of thoracic damage control would yield higher than expected survival rates for trauma thoracotomy patients with metabolic exhaustion, whereas traditional definitive chest closure (DEF) would exhibit predicted survival rates. "
01/01/2014 - "We then show that the expression of pro-inflammatory cytokines is up-regulated in the def+/- liver, which leads to distortion of the migration and the clearance of leukocytes after PH. Transforming growth factor β (TGFβ) signalling is thus activated in the wound epidermis in def+/- due to a prolonged inflammatory response, which leads to fibrosis at the amputation site. "
|3.||Transforming Growth Factors (Transforming Growth Factor)
|5.||DNA (Deoxyribonucleic Acid)
|8.||Ascorbic Acid (Vitamin C)
|9.||Estrogen Receptor alpha
|10.||Muscarinic M1 Receptor
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|4.||Transplantation (Transplant Recipients)